Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases
Artiva Biotherapeutics, Inc. will present five abstracts on its AlloNK therapeutic at EULAR 2026. These presentations will detail clinical and translational findings for AlloNK across various rheumatologic diseases, including refractory rheumatoid arthritis, Sjögren disease, and systemic sclerosis, with a late-breaking oral presentation highlighting the company's research. This follows positive initial results for AlloNK and plans to advance to a Phase 3 rheumatoid arthritis trial in 2026, expanding Artiva's clinical pipeline in autoimmune conditions.
MAY 8·Seeking Alpha▲
Artiva: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA (NASDAQ:ARTV)
Artiva Biotherapeutics (ARTV) has received a "Buy" rating due to FDA alignment for a single Phase 3 trial of AlloNK combined with rituximab for refractory rheumatoid arthritis. The company targets initiating the Phase 3 trial in 2H 2026, with data expected in 2H 2028, addressing a significant unmet need for 150K-200K U.S. patients who are unresponsive to current biologics. A recent $300M capital raise extends their operational runway beyond Q2 2027, supporting trials and pipeline expansion into other autoimmune disorders.
APR 16·Yahoo Finance▲
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham
Artiva Biotherapeutics is focusing on rheumatoid arthritis (RA) as the primary indication for its off-the-shelf NK cell therapy, expecting to release efficacy data from at least 15 RA patients in the first half of the year. The company uses non-genetically modified NK cells in combination with rituximab to achieve deep B-cell depletion, targeting a 50% ACR50 response in late-line RA patients. Artiva also highlighted the therapy's safety profile, manufacturing scalability from single cord units, and its financial runway extended into Q2 2027.
